Download PDF
Semin Respir Crit Care Med 2001; 22(1): 075-088
DOI: 10.1055/s-2001-13842
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Acute Myocardial Ischemia and Infarction: Making the Right Decisions in Antithrombotic and Reperfusion Therapies

Robert C. Hendel
  • Coronary Care Unit, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois
Further Information

Publication History

Publication Date:
31 December 2001 (online)

    Permissions and Reprints

ABSTRACT

Acute coronary syndromes, which include unstable angina and myocardial infarction (MI), have the common pathophysiological mechanism of intracoronary thrombus formation. Treatment of an acute MI initially focuses on reperfusion with thrombolysis or percutaneous coronary interventions (PCI)s. Primary or direct percutaneous interventions, with traditional angioplasty and stenting, appear to provide superior efficacy for acute MI, although temporal factors are crucial. However, antiplatelet and antithrombin therapies are also vital for the maintenance and enhancement of complete coronary perfusion and for primary management of non-Q wave myocardial infarction (NQWMI) and unstable angina. Recent advances in the pharmacological treatment include the use of direct thrombin inhibitors, low-molecular-weight heparin, and glycoprotein IIb/IIIa antagonists, all of which have shown substantial benefit for acute coronary syndromes. The article focuses on the clinical literature supporting the utility of recent therapeutic advances and outlines the current indications for such treatments.

KEYWORD

Myocardial infarction - ischemia - coronary artery disease - thrombolysis - antiplatelet - anticoagulant

REFERENCES

  • 1 De Wood A M, Spores J, Notske R N. Prevalence of total coronary artery occlusion during the early hours of transmural myocardial infarction.  N Engl J Med . 1980;  303 897
    PubMedGoogle Scholar
  • 2 Kim C B, Braunwald E. Potential benefits of late reperfusion of infarct myocardium: the open artery hypothesis.  Circulation . 1993;  88 2426-2436
    PubMedGoogle Scholar
  • 3 Braunwald E. Heart Disease: A textbook of cardiovascular medicine.  5th ed. Philadelphia: WB Saunders; 1997
    Google Scholar
  • 4 Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients.  Lancet . 1994;  343 311-322
    PubMedGoogle Scholar
  • 5 Gruppo Italiano Per Lo Studio Della Streptochinasi Ness' Infarct Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.  Lancet . 1986;  1 397
    PubMedGoogle Scholar
  • 6 EMERAS (Estudio Multicentrico Estreptoquinasa Republicas de America del Sur) Collaberative Group. Randomized trial of late thrombolysis in acute myocardial infarction.  Lancet . 1993;  342 767
    CrossrefPubMedGoogle Scholar
  • 7 LATE (Late Assessment of Thrombolytic Efficacy) Study Group. Late Assessment of Thrombolytic Efficacy (LATE) Study with alteplase 6-24 hours after onset of acute myocardial infarction.  Lancet . 1993;  342 759
    CrossrefPubMedGoogle Scholar
  • 8 Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'Infarcto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase vesus no heparin among 12,490 patients with acute myocardial infarction.  Lancet . 1990;  335 65
    PubMedGoogle Scholar
  • 9 Cannon C P, McCade C H, Diver D J. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.  J Am Coll Cardiol . 1994;  24 1602-1610
    PubMedGoogle Scholar
  • 10 ISIS-3 (Third Internation Study of Infarct Survival) Collaborative Group. A randomized trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction.  Lancet . 1992;  339 753
    PubMedGoogle Scholar
  • 11 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.  N Engl J Med . 1993;  329 673-682
    CrossrefPubMedGoogle Scholar
  • 12 Theiman D R, Coresh J, Schulman S P. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years.  Circulation . 2000;  101 2239-2246
    PubMedGoogle Scholar
  • 13 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after myocardial infarction.  N Engl J Med . 1993;  329 1615-1622
    CrossrefPubMedGoogle Scholar
  • 14 Smalling R W, Bode C, Kalbfleisch J. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infuciton in acute myocardial infarction.  Circulation . 1995;  91 2725-2732
    PubMedGoogle Scholar
  • 15 Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction.  N Engl J Med . 1997;  337 1118-1123
    CrossrefPubMedGoogle Scholar
  • 16 Assessment of the Safety and Efficacy of a New Thromlytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.  Lancet . 1999;  354 716-722
    CrossrefPubMedGoogle Scholar
  • 17 Boersman E, Akkerhuis M, Simoons M L. Primary angioplasty versus thrombolysis for acute myocardial infarction (Letter).  N Engl J Med . 2000;  342 890-891
    CrossrefPubMedGoogle Scholar
  • 18 TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction: results of the TIMI IIIB trial.  Circulation . 1994;  89 1545-1556
    PubMedGoogle Scholar
  • 19 Doorey A, Patel S, Reese C. Dangers of delay of initiation of either thrombolysis or primary angioplasty in acute myocardial infarction with increasing use of primary angioplasty.  Am J Cardiol. 1998;  811173-811177
    PubMedGoogle Scholar
  • 20 Ross A M, Coyne K S, Reiner J S. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial.  J Am Coll Cardiol . 1999;  34 1854-1862
    CrossrefPubMedGoogle Scholar
  • 21 Braunwald, E. Heart Disease: A Textbook of Cardiovascular Medicine.  Philadelphia: WB Saunders; 1997
    Google Scholar
  • 22 Bode C, Smalling R W, Berg G. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.  Circulation . 1996;  94 891-898
    PubMedGoogle Scholar
  • 23 The TIMI Study Group. The Thrombolysis in myocardial infarction trial: phase I findings.  N Engl J Med . 1985;  312 932-936
    PubMedGoogle Scholar
  • 24 Anderson J L, Karagounis L A, Califf R M. Meta-analysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction.  Am J Cardiol . 1996;  78 1-8
    PubMedGoogle Scholar
  • 25 Weaver W D, Simes R J, Betriu A. A comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review.  JAMA . 1997;  278 2093-2098
    CrossrefPubMedGoogle Scholar
  • 26 Zijlstra F, de Boer J M, Hoorntje J CA. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction.  N Engl J Med . 1993;  328 680-684
    CrossrefPubMedGoogle Scholar
  • 27 Grines C L, Browne K D, Marco J. A comparison of immediate angioplasty with thromblytic theraphy for acute myocardial infarction.  N Engl J Med . 1993;  328 673-679
    CrossrefPubMedGoogle Scholar
  • 28 Zijlstra F, Beukema W P, van't Hof W J A. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction.  J Am Coll Cardiol . 1997;  29 908-912
    CrossrefPubMedGoogle Scholar
  • 29 Michels K B, Yusef S. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates?.  <~>A quantitative overview (meta-analysis) of randomized clinical trials. Circulation . 1995;  91 476
    PubMedGoogle Scholar
  • 30 Gibbons R J, Holmes D R, Reeder G S. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for mycoardial infarction.  N Engl J Med . 1993;  328 685-691
    CrossrefPubMedGoogle Scholar
  • 31 Every N R, Parsons L S, Hlatky M. A comparison of thrombolytic therapy with primary angioplasty for acute myocardial infarction.  N Engl J Med . 1996;  335 1253-1260
    CrossrefPubMedGoogle Scholar
  • 32 Tiefenbrunn A J, Chandra N C, French W J. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: report from the Second National Registry of Myocardial Infarction (NRMI-2).  J Am Coll Cardiol . 1998;  31 1240-1245
    CrossrefPubMedGoogle Scholar
  • 33 The global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO IIb) angioplasty substudy investigators: a clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med .  1997;  336 1621-1628
    PubMedGoogle Scholar
  • 34 Zijlstra F, Hoorntje J CA, de Boer J M. Long-term benefit of primary angioplasty compared with thrombolytic therapy for acute myocardial infarction.  N Engl J Med . 1999;  341 1413-1419
    CrossrefPubMedGoogle Scholar
  • 35 Stone G W, Grines C L, Rothbaum D. Analysis of the relative costs and effectiveness of primary angioplasty vs tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial.  J Am Coll Cardiol . 1997;  29 901-907
    CrossrefPubMedGoogle Scholar
  • 36 Horie H, Takahashi M, Minai K. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty.  Circulation . 1998;  98 2377-2382
    CrossrefPubMedGoogle Scholar
  • 37 Grines C L, Cox D A, Stone G W. Coronary angiolasty with or without stent implantation for acute myocardial infarction.  N Eng J Med . 1999;  341 1949-1956
    CrossrefPubMedGoogle Scholar
  • 38 Garcia E, Elizaga J, Perez-Castellano N. Primary angioplasty versus systemic thrombolysis in anterior myocadial infarction.  J am Coll Cardiol . 1999;  33 605-611
    CrossrefPubMedGoogle Scholar
  • 39 Berger A K, Schulman K A, Gersh B J. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients.  JAMA . 1999;  282 341-348
    CrossrefPubMedGoogle Scholar
  • 40 Riberio E E, Silva L A, Carneiro R R. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction.  J Am Coll Cardiol . 1993;  276-280
    PubMedGoogle Scholar
  • 41 Holmes D R, White H D, Pieper K S. Effect of age on outcome with primary angioplasty versus thrombolysis.  J Am Coll Cardiol . 1999;  33 412-419
    CrossrefPubMedGoogle Scholar
  • 42 Hochman J S, Sleeper L A, Webb J G. Early revascularization in acute myocardial infarction complicated by cardiogenic shock: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Trial.  N Engl J Med . 1999;  341 625-634
    CrossrefPubMedGoogle Scholar
  • 43 Group SSWIFTTS. SWIFT trial of delayed elective intervention v. conservative treatment after thrombolysis with anistreplase in acute myocardial infarction.  BMJ . 1991;  302 555
    PubMedGoogle Scholar
  • 44 Rogers W J, Baim D S, Gore J M. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator: results of the Thromolysis in Myocardial Infarction (TIMI) Phase II-A Trial.  Circulation . 1990;  81 1257
    PubMedGoogle Scholar
  • 45 Ellis S G, Mooney M R, George B S. Randomized trial of late elective angioplasty versus conservative management for patients with residual stenoses after thrombolytic treatment of myocardial infarction: Treatment of Post-Thrombolytic Stenoses (TOPS) Study.  Circulation . 1992;  86 1400
    CrossrefPubMedGoogle Scholar
  • 46 O'Neill W W, Weintraub R, Grines C L. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy for acute myocardial infarction.  Circulation . 1992;  86 1710-1717
    PubMedGoogle Scholar
  • 47 Grines C L. Primary angioplasty-the strategy of choice.  N Engl J Med . 1996;  335 1313-1316
    PubMedGoogle Scholar
  • 48 Berger P B, Ellis S G, Homes D R. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction; results from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) Trial.  Circulation . 1999;  100 14-20
    PubMedGoogle Scholar
  • 49 Rupprecht H J, vom Dahl J, Terres W. Cardioprotective effects of the Na+/H+ exchange inhibitor cariporide in patients with acute anterior myocardial infarction undergoing direct PTCA.  Circulation . 2000;  101 2902-2908
    CrossrefPubMedGoogle Scholar
  • 50 Theroux P, Ouimet H, McCans J. Aspirin, heparin, or both to treat acute unstable angina.  N Engl J Med . 1988;  319 1105-1111
    CrossrefPubMedGoogle Scholar
  • 51 Lewis H D, Davis J W, Archibald D G. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina.  N Engl J Med . 1983;  309 396-403
    CrossrefPubMedGoogle Scholar
  • 52 RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.  Lancet . 1990;  336 827-830
    CrossrefPubMedGoogle Scholar
  • 53 Theroux P, Waters D, Lam J. Reactivation of unstable angina after the discontinuation of heparin.  N Engl J Med . 1992;  327 141-145
    PubMedGoogle Scholar
  • 54 ISIS-2 Collaberative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction.  Lancet . 1988;  ii 349-360
    PubMedGoogle Scholar
  • 55 Antiplatelets Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment.  Br Med J . 1988;  296 320-321
    PubMedGoogle Scholar
  • 56 Yeghiazarians Y, Braunstein J B, Askari A, Stone P H. Unstable angina pectoris.  N Engl J Med . 2000;  342 101-114
    CrossrefPubMedGoogle Scholar
  • 57 CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet . 1996;  348 1229-1239
    PubMedGoogle Scholar
  • 58 Madan M, Berkowitz S D, Tcheng J E. Glycoprotein IIb/IIIa Integrin Blockade.  Circulation . 1998;  98 2629-2635
    CrossrefPubMedGoogle Scholar
  • 59 Zaacks S M, Liebson P R, Calvin J E. Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?.  J Am Coll Cardiol . 1999;  33 107-118
    CrossrefPubMedGoogle Scholar
  • 60 Borsma E, Akkerhuis M, Theroux P. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.  Circulation . 1999;  100 2045-2048
    PubMedGoogle Scholar
  • 61 Platelet Receptor Inhibition in Ischemic Syndrome Management: PRISM Study Investigators. A comparison of aspirin plus tirfiban with aspirin plus heparin for unstable aninga.  N Engl J Med . 1998;  338 1498-1505
    CrossrefPubMedGoogle Scholar
  • 62 Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.  N Engl J Med . 1998;  338 1488-1497
    CrossrefPubMedGoogle Scholar
  • 63 PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with epitifibatide in patients with acute coronary syndromes.  N Engl J Med . 1998;  339 436-443
    CrossrefPubMedGoogle Scholar
  • 64 PARGAON Investigators. International, randomized controlled trial of lamifiban (a platelet gycoprotein IIb/IIIa inhibitor, heparin, or both in unstable angina.  Circulation . 1998;  97 2386-2395
    PubMedGoogle Scholar
  • 65 Hamm C W, Ravkilde J, Gerhardt W. The prognostic value of serum troponin T in unstable angina.  N Engl J Med . 1992;  327 146-150
    PubMedGoogle Scholar
  • 66 Hamm C W, Heeschen C, Goldman B. Benefit of abciximab in patients with refractory unstable angina to serum T levels.  N Engl J Med . 1999;  340 1623-1629
    CrossrefPubMedGoogle Scholar
  • 67 Strategies for patency Enhancment in the Emergency Department Group. Trial of abciximab with and without low dose reteplase for acute myocardial infarction.  Circulation . 2000;  101 2788-2794
    PubMedGoogle Scholar
  • 68 Antman E M, Giugliano R, Gibson C. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial.  Circulation . 1999;  99 2720-2732
    PubMedGoogle Scholar
  • 69 Mark D B, Harrington R A, Lincoff M. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.  Circulation . 2000;  101 366-371
    PubMedGoogle Scholar
  • 70 Oler A, Whooley M A, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis.  JAMA. 1996; 
    PubMedGoogle Scholar
  • 71 Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin.  N Engl J Med . 1992;  327 141-145
    PubMedGoogle Scholar
  • 72 Greinacher A, Janssens U, Berg G. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-inducd thrombocytopenia. Heparin-Associated Study (HAT) Investigators.  Circulation . 1999;  100 587-593
    CrossrefPubMedGoogle Scholar
  • 73 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes.  N Engl J Med . 1996;  335 775-782
    CrossrefPubMedGoogle Scholar
  • 74 Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularizaiton procedures in patients with acute myocardial ischemia without ST elevation: a randomized trial.  Lancet . 1999;  353 429-438
    CrossrefPubMedGoogle Scholar
  • 75 Kong D F, Topol E J, Bittl J A. Clinical outcomes of bivalirudin for ischemic heart disedase.  Circulation . 1999;  100 2049-2053
    PubMedGoogle Scholar
  • 76 Antman E M. Hirudin in acute mycoardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial.  Circulation . 1996;  94 911-921
    CrossrefPubMedGoogle Scholar
  • 77 White H D, Aylward B M, Frey M J. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO).  Circulation . 1997;  96 2155-2161
    PubMedGoogle Scholar
  • 78 Swahn E, Wallentin L, for the FRISC Study Group. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disese (FRISC).  Am J Cardiol . 1997;  80 25E-29E
    CrossrefPubMedGoogle Scholar
  • 79 Klein W, Buchwald W, Hillis S E. Comparison of low-molecular-weight heparin with infractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease: fragmin in unstable coronary artery disease study (FRIC).  Circulation . 1997;  96 61-68
    PubMedGoogle Scholar
  • 80 Fragmin and Fast Revascularization during Instability in Coronary Artery Disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary arery disease: FRISC II prospective randomised multicentre study.  Lancet . 1999;  354 701-707
    CrossrefPubMedGoogle Scholar
  • 81 Cohen M, Demers C, Gurfinkel E P. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease.  N Engl J Med . 1997;  337 447-452
    CrossrefPubMedGoogle Scholar
  • 82 Antman E M, McCabe C H, Gurfinkel E P. Enoxaparin prevents death and cardiac ischemic events in unstable angina/Non-Q wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 11B Trial.  Circulation . 1999;  100 1593-1601
    PubMedGoogle Scholar
  • 83 Antman E M, Cohen M, Radley D. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis.  Circulation . 1999;  100 1602-1608
    CrossrefPubMedGoogle Scholar
  • 84 Kaul S, Shah P K. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?.  J Am Coll Cardiol . 2000;  35 1699-1712
    CrossrefPubMedGoogle Scholar
  • 85 Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection.  J Am Coll Cardiol . 1997;  29 43-49
    CrossrefPubMedGoogle Scholar
  • 86 Mark D B, Cowper P A, Bekowitz S D. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial.  Circulation . 1998;  97 1702-1707
    PubMedGoogle Scholar
  • 87 O'Brien B J, Willan A, Blackhouse G. Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?.  Am Heart J . 2000;  139 423-429
    PubMedGoogle Scholar
      >